🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› London
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in London

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2846 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 20 Sep 2026, 03:15 UTC
2846
Studies in scope
industry-sponsored, all four open statuses
1377
Recruiting now
open to new participants
539
Lead sponsors
across recruiting studies
Top sites
London 2003 Manchester 674 Birmingham 469 Glasgow 437 Cambridge 416
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca136 Merck Sharp & Dohme LLC99 Hoffmann-La Roche80 Janssen Research & Development, LLC73 Novartis Pharmaceuticals72
Site city
London2003 Manchester674 Birmingham469 Glasgow437 Cambridge416
All 426 cities
Target enrolment
to
2003 of 2846 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris
NCT07532603Lichen Planopilaris
Priovant Therapeutics, Inc.
Phase 2/3
342
Salford, Glasgow, Brighton, London, Wrexham
2026-03-19
Recruiting
Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours
NCT07446855Solid Tumours
AstraZeneca
Phase 1/2
180
Cambridge, London, Sutton
2026-03-17
Recruiting
A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT
NCT07387367Adenovirus Infections
SymBio Pharmaceuticals
Phase 3
180
Birmingham, Leeds, London, Manchester, Newcastle upon Tyne, Sheffield, Sutton
2026-03-17
Recruiting
A Study of AIR-001 in Adults With Alpha-1 Antitrypsin Deficiency (AATD)
NCT07431112Alpha 1 Antitrypsin Deficiency
AIRNA Corporation
Phase 1
54
Cambridge, London, Southampton
2026-03-17
Recruiting
Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs)
NCT07457580Type 1 Diabetes
Sanofi
Observational
60
Birmingham, London
2026-03-16
Recruiting
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
NCT07291076Hepatocellular Carcinoma (HCC)
Bristol-Myers Squibb
Phase 1/2
198
London, Glasgow, Metropolitan Borough of Wirral
2026-03-16
Recruiting
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
NCT07351045Obesity or Overweight
Hoffmann-La Roche
Phase 3
2,000
Soham, Chippenham, Airdrie, Birmingham, Glasgow, Leicester, London, Newcastle upon Tyne
2026-03-16
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
NCT07221149Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Bristol-Myers Squibb
Phase 2/3
690
London, Oxford, Sutton, Glasgow, Manchester
2026-03-13
Recruiting
A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder
NCT07475806Muscle-invasive Bladder Cancer
Astellas Pharma Global Development, Inc.
Phase 2
240
London
2026-03-12
Recruiting
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
NCT07361510Non-Small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb
Phase 3
750
Aberdeen, Middlesbrough, Norwich, Sutton, Cambridge, Cardiff, Guildford, London
2026-03-12
Recruiting
A Clinical Study to Assess Sutacimig in Participants With Congenital Factor VII Deficiency
NCT07347249Congenital Factor VII Deficiency
Hemab ApS
Phase 2
18
London
2026-03-11
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
NCT07282574Progressive Multiple Sclerosis
Hoffmann-La Roche
Phase 2
360
Truro, London, Glasgow, Cardiff, Salford, Swansea
2026-03-10
Recruiting
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07491445Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
Revolution Medicines, Inc.
Phase 3
900
Torquay, Birmingham, Cambridge, London, Manchester
2026-03-09
Recruiting
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
NCT07441642Geographic Atrophy Secondary to Age-related Macular Degeneration
Novartis Pharmaceuticals
Phase 2
272
Bristol, London, Newcastle upon Tyne, Southampton
2026-03-09
Recruiting
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
NCT07284849CRC (Colorectal Cancer)
Incyte Corporation
Phase 3
700
Bristol, Cardiff, Leeds, London, Maidstone, Manchester, Sutton
2026-03-05
Recruiting
Study of TGM-312-SC01 in Healthy Participants and Adults With MASH
NCT07427680Healthy Participants, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Tangram Therapeutics Plc
Phase 1/2
99
London
2026-03-03
Recruiting
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
NCT07288398Pulmonary Hypertension Associated With HFpEF
Tenax Therapeutics, Inc.
Phase 3
540
Cambridge, Glasgow, London, Sheffield, Swindon
2026-03-03
Recruiting
A Study to Evaluate ALN-4915 in Adult Healthy Volunteers
NCT07535606Healthy Volunteers
Alnylam Pharmaceuticals
Phase 1
44
London
2026-03-02
Not yet open
Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects With Reduced Ejection Fraction
NCT07403058Heart Failure With Reduced Ejection Fraction (HFrEF)
Axon Therapies, Inc.
Not applicable
50
Leeds, London
2026-03-01
Active, closed
Demographics, Clinical Characteristics and Outcomes in Resected Non-Small Cell Lung Cancer Patients Receiving Immunotherapy in Europe and Canada
NCT07718139Non-Small Cell Lung Cancer
Bristol-Myers Squibb
Observational
300
London
2026-02-28
Recruiting
Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide
NCT07454837Chronic Hepatitis D
Mirum Pharmaceuticals, Inc.
Phase 2/3
120
Cottingham, Cardiff, London, Manchester
2026-02-26
Recruiting
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
NCT07391657Relapsed Refractory Multiple Myeloma
AstraZeneca
Phase 3
508
Birmingham, Bristol, Glasgow, Scotland, London
2026-02-23
Recruiting
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
NCT07284758Multiple Myeloma, Relapsed/Refractory Multiple Myeloma
C4 Therapeutics, Inc.
Phase 2
100
London
2026-02-18
Recruiting
Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia
NCT07288333Schizophrenia
Neurocrine Biosciences
Phase 2
120
London, Oxford
2026-02-16
Recruiting
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
NCT07220083Focal Segmental Glomerulosclerosis
Boehringer Ingelheim
Phase 3
286
Bebington, Bradford, Cambridge, Leicester, London, Salford
2026-02-16
Rows per page Showing 126–150 of 2003
Previous 4 5 6 7 8 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 20 September 2026. https://priyalifescience.com/clinical-trials-uk/city/london

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.